{"id":"W4387825574","doi":"10.1016/j.annonc.2023.09.2000","title":"854O INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Hazard ratio; Internal medicine; Head and neck squamous-cell carcinoma; Cetuximab; Clinical endpoint; Oncology; Interim analysis; Cancer; Progression-free survival; Head and neck cancer; Confidence interval; Phases of clinical research; Urology; Gastroenterology; Chemotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009816081,0.00124806,0.001478971,0.0003359815,0.0003672911,0.0007628106,0.0007543945,0.001011556,0.005143684],"category_scores_gemma":[0.0005185762,0.0006063189,0.001057344,0.0002442771,0.0006602895,0.0005931759,0.0003871309,0.002529532,0.001422059],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000663347,"about_ca_system_score_gemma":0.00115241,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001859728,"about_ca_topic_score_gemma":0.005173471,"domain_scores_codex":[0.9996921,0.0001177425,0.00001310355,0.00006988538,0.00003145886,0.00007573575],"domain_scores_gemma":[0.9996496,0.00004302063,0.00006343659,0.000022932,0.00002168559,0.000199302],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8731171,0.04683263,0.004447013,0.0004568288,0.001312847,0.00006023044,0.0001666784,0.0007930976,0.03274776,0.0001662941,0.00182137,0.03807818],"study_design_scores_gemma":[0.6788242,0.303459,0.01113285,0.00002538608,0.0008457821,0.00006711926,0.00005104884,0.0006347732,0.003153461,0.00009652085,0.00168818,0.00002166092],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955677,0.0006455817,0.0002609737,0.0002002574,0.0001108335,0.001216109,0.0006316021,0.00009158041,0.001275196],"genre_scores_gemma":[0.988789,0.001099786,0.001124012,0.0006246829,0.0001780229,0.001614167,0.001882349,0.00003718405,0.004650733],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005143684,"threshold_uncertainty_score":0.01720732,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06185240039931168,"score_gpt":0.3751156339257055,"score_spread":0.3132632335263938,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}